Analysts Set Cardlytics, Inc. (NASDAQ:CDLX) Price Target at $6.92

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given an average rating of “Hold” by the seven analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $6.92.

Several analysts have recently weighed in on the stock. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. Bank of America cut Cardlytics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $4.00 to $3.50 in a report on Thursday, August 15th. Evercore ISI started coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price for the company. Finally, Northland Capmk lowered shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th.

Cardlytics Stock Up 3.4 %

Shares of NASDAQ:CDLX opened at $3.93 on Friday. The company has a market cap of $199.73 million, a price-to-earnings ratio of -0.64 and a beta of 1.61. Cardlytics has a one year low of $2.89 and a one year high of $20.52. The firm has a fifty day moving average price of $3.74 and a two-hundred day moving average price of $6.14. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.18. The firm had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company’s revenue was down 15.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.26) EPS. Analysts anticipate that Cardlytics will post -1.52 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now owns 178,519 shares in the company, valued at approximately $687,298.15. This represents a 11.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares of the company’s stock, valued at approximately $399,529.83. The trade was a 17.74 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 68,691 shares of company stock worth $237,767. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cardlytics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Canton Hathaway LLC lifted its position in Cardlytics by 95.7% during the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after buying an additional 2,200 shares during the period. Atom Investors LP bought a new position in shares of Cardlytics in the 3rd quarter worth about $33,000. XTX Topco Ltd purchased a new position in Cardlytics during the 2nd quarter valued at about $107,000. Banco Santander S.A. bought a new stake in Cardlytics during the first quarter worth about $199,000. Finally, SG Americas Securities LLC purchased a new stake in Cardlytics in the third quarter worth about $45,000. 68.10% of the stock is owned by hedge funds and other institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.